Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
French drugmaker Sanofi sued Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. company's plans to produce its own version of the drug.
Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion. It is set to lose patent protection in the United States, the world's largest pharmaceutical market, in February 2015.
Sanofi's lawsuit, filed on Thursday, triggers an automatic 30-month stay of approval by the U.S. Food and Drug Administration, keeping Lilly's biosimilar drug off the U.S. market until mid-2016, more than a year later than its previously expected launch date.
http://whtc.com/news/articles/2014/...ly-over-patents-for-top-selling-insulin-drug/
Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion. It is set to lose patent protection in the United States, the world's largest pharmaceutical market, in February 2015.
Sanofi's lawsuit, filed on Thursday, triggers an automatic 30-month stay of approval by the U.S. Food and Drug Administration, keeping Lilly's biosimilar drug off the U.S. market until mid-2016, more than a year later than its previously expected launch date.
http://whtc.com/news/articles/2014/...ly-over-patents-for-top-selling-insulin-drug/